Evidence map›Paper›PMID 36376731›Full record

ArticleInfectious diseases and therapy2023

A Response to: Letter to the Editor Regarding 'Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age'.

Mark H Rozenbaum, Johnna Perdrizet, Xiuyan Li, Matt D Wasserman, Lindsay R Grant, Kyla Hayford, Raymond A Farkouh

Open access · goldAbstract readLetter
In one paragraph

Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Mark H RozenbaumHealth Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands. Mark.rozenbaum@pfizer.com.
Johnna PerdrizetHealth Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
Xiuyan LiHealth Economics and Outcomes Research, Pfizer Inc, New York, NY, USA.
Matt D WassermanPatient and Health Impact, Pfizer Inc, New York, NY, USA.
Lindsay R GrantVaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, New York, NY, USA.
Kyla HayfordVaccines Medical Development and Scientific and Clinical Affairs, Pfizer Inc, New York, NY, USA.
Raymond A FarkouhHealth Economics and Outcomes Research, Pfizer, Capelle aan den Ijssel, The Netherlands.
Pfizer (United States) · USPfizer (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36376731
PMCPMC9868018
OpenAlexW4308992126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.